Stockreport

Cardiff Oncology's Onvansertib: A Speculative Buy With Promising Data [Seeking Alpha]

Cardiff Oncology, Inc.  (CRDF) 
PDF Onvansertib's promising early data suggest that it overcomes treatment resistance, improves response rates, and extends progression-free survival. Ongoing Phase 2 tri [Read more]